ReviewViruses2026
Disability and Biomedical HIV Prevention: The Missing Equity Dimension.
Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The remarkable success of biomedical HIV prevention has transformed the global response to HIV through the widespread implementation of oral pre-exposure prophylaxis (PrEP), long-acting antiretroviral agents and HIV self-testing. However, ensuring equitable access to these interventions remains a major challenge. Although more than one billion people worldwide live with a disability, disability has received surprisingly little attention within contemporary HIV prevention research and implementation. This narrative review examines the intersection between disability and modern HIV prevention, integrating evidence on sexual and reproductive health, structural barriers to healthcare and the evolving landscape of biomedical prevention. The available literature suggests that people with disabilities experience persistent inequalities in access to sexuality education, HIV information, testing and preventive services, largely due to physical, communication and systemic barriers rather than biological vulnerability. Despite these well-documented disparities, disability is rarely incorporated into PrEP implementation studies, HIV prevention policies or differentiated service delivery models. We argue that disability should be considered an implementation and health equity challenge rather than a pharmacological one. The effectiveness of biomedical prevention ultimately depends on healthcare systems capable of delivering accessible, person-centred and inclusive services. Integrating disability into implementation science, clinical practice and public health policy represents an essential step toward achieving equitable HIV prevention. As HIV prevention continues to evolve, accessibility should be recognised not as an optional adaptation but as a fundamental component of high-quality prevention programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.